NASDAQ
24.18USD
-1.57 (-6.10%)
We have scored 18 news catalysts on Immunome, Inc. (IMNM) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.46). Most of the impact sits in price momentum and institutional appeal.
Market cap
2.3B
P/E
—
EPS
—
Beta
2.13
52W range
10-30.06
Day range
24.01–25.88
Open
25.88
Prev close
25.75
Volume
1.5M
Avg volume
1.3M
Dividend
0.00
IPO
2020-10-02
No scored news tagged IMNM or its network in the window yet.
Show more IMNM articles →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Immunome, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IMNM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
